Seasoned drugs push Roche sales higher in third quarter

Roche reported a 15.3% increase in turnover to CHF 11.3 billion (€9.3 billion) in the third quarter on the strength of sales of three established drugs, MabThera (rituximab), Herceptin (trastuzumab) and Avastin (bevacizumab).